tradingkey.logo

Pulse Biosciences Inc

PLSE

18.520USD

+2.250+13.83%
Close 09/18, 16:00ETQuotes delayed by 15 min
1.25BMarket Cap
LossP/E TTM

Pulse Biosciences Inc

18.520

+2.250+13.83%

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated2025-09-17

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Strong Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
38 / 207
Overall Ranking
135 / 4723
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 1 analysts
Strong Buy
Current Rating
22.000
Target Price
+32.21%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.
Fairly Valued
The company’s latest PE is -15.12, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 55.62M shares, decreasing 0.79% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.22M shares of this stock.

Financial Health

Currency: USD Updated2025-09-17

The company's current financial score is 6.72, which is lower than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score
6.72
Change
0

Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data

Quality of Earnings

7.20

Operational Efficiency

2.75

Growth Potential

6.62

Shareholder Returns

7.03

Company Valuation

Currency: USD Updated2025-09-17

The company’s current valuation score is 1.20, which is lower than the Healthcare Equipment & Supplies industry's average of 2.00. Its current P/E ratio is -15.12, which is -66.15% below the recent high of -5.12 and -12.30% above the recent low of -16.98.

Score

Industry at a Glance

Previous score
2.00
Change
-0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 38/207
No Data

Earnings Forecast

Currency: USD Updated2025-09-17

The company’s current earnings forecast score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for Pulse Biosciences Inc is 22.00, with a high of 22.00 and a low of 22.00.

Score

Industry at a Glance

Previous score
10.00
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 1 analysts
Strong Buy
Current Rating
22.000
Target Price
+35.22%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

94
Total
4
Median
7
Average
Company name
Ratings
Analysts
Pulse Biosciences Inc
PLSE
1
Boston Scientific Corp
BSX
36
Edwards Lifesciences Corp
EW
35
Intuitive Surgical Inc
ISRG
34
Veeva Systems Inc
VEEV
32
Thermo Fisher Scientific Inc
TMO
31
1
2
3
...
19

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated2025-09-17

The company’s current price momentum score is 9.16, which is higher than the Healthcare Equipment & Supplies industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 17.80 and the support level at 14.29, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
9.34
Change
-0.18

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(2)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
0.534
Neutral
RSI(14)
68.822
Neutral
STOCH(KDJ)(9,3,3)
87.501
Buy
ATR(14)
0.911
High Vlolatility
CCI(14)
248.573
Overbought
Williams %R
2.899
Overbought
TRIX(12,20)
-0.010
Sell
StochRSI(14)
100.000
Overbought
Moving Average
Sell(0)
Neutral(0)
Buy(6)
Indicators
Value
Direction
MA5
16.338
Buy
MA10
15.665
Buy
MA20
15.766
Buy
MA50
15.571
Buy
MA100
16.021
Buy
MA200
17.133
Buy

Institutional Confidence

Currency: USD Updated2025-09-17

The company’s current institutional recognition score is 7.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 82.69%, representing a quarter-over-quarter increase of 0.03%. The largest institutional shareholder is The Vanguard, holding a total of 1.22M shares, representing 1.81% of shares outstanding, with 4.60% increase in holdings.

Score

Industry at a Glance

Previous score
7.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Duggan (Robert William)
48.60M
--
The Vanguard Group, Inc.
Star Investors
839.06K
-26.55%
BlackRock Institutional Trust Company, N.A.
1.21M
-2.09%
Zanganeh (Mahkam)
873.47K
--
BofA Global Research (US)
777.76K
-1.36%
Geode Capital Management, L.L.C.
465.72K
+1.07%
State Street Global Advisors (US)
419.24K
-11.60%
Griffin Asset Management, Inc.
233.56K
-1.68%
Northern Trust Investments, Inc.
200.07K
-4.15%
Charles Schwab Investment Management, Inc.
149.64K
+0.29%
1
2

Risk Assessment

Currency: USD Updated2025-09-17

The company’s current risk assessment score is 4.16, which is higher than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 1.78. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
4.16
Change
0
Beta vs S&P 500 index
1.78
VaR
+8.31%
240-Day Maximum Drawdown
+41.04%
240-Day Volatility
+69.80%
Return
Best Daily Return
60 days
+11.19%
120 days
+11.19%
5 years
+40.12%
Worst Daily Return
60 days
-6.64%
120 days
-13.15%
5 years
-34.44%
Sharpe Ratio
60 days
+0.74
120 days
+0.37
5 years
+0.47
Risk Assessment
Maximum Drawdown
240 days
+41.04%
3 years
+55.90%
5 years
+97.22%
Return-to-Drawdown Ratio
240 days
-0.04
3 years
+4.16
5 years
-0.01
Skewness
240 days
+0.24
3 years
+1.45
5 years
+0.80
Volatility
Realised Volatility
240 days
+69.80%
5 years
+99.04%
Standardised True Range
240 days
+6.79%
5 years
+5.96%
Downside Risk-Adjusted Return
120 days
+55.05%
240 days
+55.05%
Maximum Daily Upside Volatility
60 days
+44.23%
Maximum Daily Downside Volatility
60 days
+34.40%
Liquidity
Average Turnover Rate
60 days
+0.26%
120 days
+0.27%
5 years
--
Turnover Deviation
20 days
-26.97%
60 days
-23.69%
120 days
-20.47%

Peer Comparison

Healthcare Equipment & Supplies
Pulse Biosciences Inc
Pulse Biosciences Inc
PLSE
6.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
7.91 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Insulet Corp
Insulet Corp
PODD
7.86 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stevanato Group SpA
Stevanato Group SpA
STVN
7.84 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Abbott Laboratories
Abbott Laboratories
ABT
7.68 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Transmedics Group Inc
Transmedics Group Inc
TMDX
7.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI